Investigator-driven clinical research has a central role
in our efforts to improve breast cancer treatment.
A particular focus is translational research to develop new,
tailored therapies to achieve the best outcome for individual patients.
Several of our clinical trials are being conducted in collaboration
with international research organizations.
- A randomized phase II comparative study of preoperative chemotherapies including Trastuzumab + Cyclophosphamide + Docetaxel for operable HER2 positive breast cancer
- ALTTO (JBCRG-08)
- GLOBAL ALTTO（JBCRG-08）
- A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer (BIG 2-06 / N063D / EGF 106708.)
- Phase II study of combination therapy of preoperative Letrozole and low-dose Metronomic Cyclophosphamide for postmenopausal / hormone receptor positive breast cancer
- Evaluation of the response rate, the pathological response and the safety of neoadjuvant Letrozole for postmenopausal women with hormone receptor positive, operable and primary breast which confirmed SD or PD in prior anthracycline-containing chemotherapy.
- Phase II study of Letrozole and Docetaxel as preoperative chemotherapy in postmenopausal/hormone receptor positive / neo-adjuvant anthracycline refractory primary breast cancer
- Study of letrozole in postmenopausal patients with breast cancer - exploratory research on expression of hormone receptors and its clinical effect -
Voluntary Organization JBCRG